Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 7/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.48 |
| ▸ | GSK3A | P49840 | 3/20 | 0.47 |
| ▸ | GSK3B | P49841 | 3/20 | 0.47 |
| ▸ | TOP1 | P11387 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.43 |
| ▸ | WEE1 | P30291 | 4/20 | 0.42 |
| ▸ | PRKCA | P17252 | 3/20 | 0.41 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5344922 | 0.91 | CDK5 (0.48) | CDK5CDK5R1DYRK1AGSK3AGSK3B | |
| SCHEMBL5333886 | 0.86 | CDK5 (0.43) | CDK5CDK5R1 | |
| SCHEMBL5337243 | 0.86 | CDK5 (0.42) | CDK5CDK5R1DYRK1AGSK3AGSK3B | |
| SCHEMBL5337910 | 0.86 | MAP3K11 (0.46) | CDK5CDK5R1DYRK1AGSK3AGSK3B | |
| SCHEMBL5343061 | 0.83 | CHEK1 (0.59) | CDK5CDK5R1DYRK1AGSK3AGSK3B | |
| SCHEMBL5334001 | 0.80 | CDK2 (0.46) | CDK5CDK5R1 | |
| SCHEMBL5337017 | 0.77 | CDK5 (0.42) | CDK5CDK5R1DYRK1AGSK3AGSK3B | |
| SCHEMBL5334145 | 0.74 | CDK5 (0.52) | CDK5CDK5R1DYRK1AGSK3AGSK3B | |
| SCHEMBL5337995 | 0.73 | MPO (0.45) | CDK5CDK5R1 | |
| SCHEMBL5334652 | 0.71 | MPO (0.50) | ROCK2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202255-B2 | Substituted [1,4] benzodioxino[2,3-e] isoindole derivatives, method for preparing and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2007-04-10 | — | — | US | disclosed |
| EP-1587810-B1 | NOVEL SUBSTITUTED 1,4|BENZODIOXINO 2,3-E|ISOINDOLE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2006-11-08 | — | — | EP | disclosed |
| US-20060040930-A1 | Novel substituted [1,4] benzodioxino[2,3-e] isoindole derivatives, method for preparing and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040930-A1 | Novel substituted [1,4] benzodioxino[2,3-e] isoindole derivatives, method for preparing and pharmaceutical compositions containing same | CYP11B2, CYP2F1, CYP3A43 | CDK5 1566/4885CDK5R1 1020/4885DYRK1A 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.